Yale’s David Spiegel inspires another immuno-oncology R&D spinout focused on Antibody Recruiting Molecules
A year ago, a joint venture between Bristol-Myers Squibb and Allied Minds picked up some immuno-oncology molecules from the lab of Yale’s David Spiegel. Now his work on Antibody Recruiting Molecules — which lure in antibodies to a specific surface protein in order to destroy diseased cells — is being used to spin out a new biotech called Kleo Pharmaceuticals, which plans to go after cancer and infectious diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.